Essa Pharma
Press Releases

Subscribe to Alerts

     

* Required Fields
ESSA Pharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.

David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in one-on-one meetings

Presentation Details

Event: Jefferies London Healthcare Conference 
Format: Fireside Chat 
Date: Thursday, November 17, 2022 
Time: 3:15 p.m. GMT / 10:15 a.m. ET

Event: Piper Sandler 34th Annual Healthcare Conference 
Format: Fireside Chat 
Date: Tuesday, November 29, 2022 
Time: 4:30 p.m. ET

A live webcast of the Jefferies fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

SOURCE ESSA Pharma Inc

For further information: Company Contact: Peter Virsik, Chief Operating Officer, ESSA Pharma Inc., Contact: (778) 331-0962, Email: pvirsik@essapharma.com; Investor Relations Contact: Xuan Yang, Solebury Strategic Communications, Contact: (646) 378-2975, Email: xyang@soleburystrat.com; Media Contact: Zara Lockshin Solebury Strategic Communications, Contact: (646) 378-2960, Email: zlockshin@soleburystrat.com